Clinical Trial Search

Phase 3 N=1,825 A Phase 3 Study of Tanezumab for Chronic Low Back Pain

Low Back Pain

Primary: Change From Baseline in Average Low Back Pain Intensity (LBPI) Score for Tanezumab Versus (Vs) Placebo at Week 16 — -2.68; -2.98; -3.08; -2.81 units on a scale — p=0.1117

Pfizer Results Feb 2020 4.9% serious AE View details

Phase 3 N=88 Nifedipine for Acute Tocolysis of Preterm Labor

Preterm Labor

Primary: Number of Participants With Preterm Birth — 24; 20 Participants

University of Texas Southwestern Medical Center Results Feb 2020 0.0% serious AE View details

Phase 3 N=196 A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.

Hyperkalemia

Primary: Percentage of Responders — 41.2; 1.0 Percentage of participants — p=<0.001

AstraZeneca Results Feb 2020 7.7% serious AE View details

Phase 3 N=350 A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

Carcinoma, Renal Cell

Primary: Progression-free Survival (PFS) — 5.59; 3.88 Months — p=0.0165

AVEO Pharmaceuticals, Inc. Results Feb 2020 43.2% serious AE View details

Phase 3 N=187 WallFlex Biliary Fully Covered (FC) Benign Stricture Study

Biliary Stricture

Primary: Stent Removability — 132 Participants

Boston Scientific Corporation Results Feb 2020 27.3% serious AE View details

Phase 3 N=140 Safety and Tolerability of Risperidone Implants

Schizophrenia

Primary: Number of Participants With Treatment-related Adverse Events as Assessed

Braeburn Pharmaceuticals Results Feb 2020 View details

Phase 3 N=3,706 Providing Free Nicotine Patches to Quitline Smokers

Smoking Cessation

Primary: Number of Participants With Six Months Prolonged Abstinence — 61; 76; 151 Participants

University of California, San Diego Results Feb 2020 0.0% serious AE View details

Phase 3 N=380 SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

Spondyloarthritis

Primary: Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8 (Treatment Period 1) — 91; 19; 188; 73 Participants — p=0.0264

Novartis Pharmaceuticals Results Feb 2020 1.2% serious AE View details

Phase 3 N=906 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis · Meningococcal Meningitis · Meningococcal Infections

Primary: Percentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menomune®…

Sanofi Pasteur, a Sanofi Company Results Feb 2020 3.3% serious AE View details

Phase 3 N=16 Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied

Glaucoma, Neovascular

Primary: Change in Intraocular Pressure (IOP) From Baseline to Week 1 — -8.3 mmHg — p=0.0004

Bayer Results Feb 2020 6.3% serious AE View details

Phase 3 N=560 Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year

National Institute of Diabetes and Digestive and… Results Feb 2020 0.0% serious AE View details

Phase 3 N=55 Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

Moderate to Severe Convexity of Submental Fat · Safety · Efficacy

Primary: Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating…

Kythera Biopharmaceuticals Results Feb 2020 1.8% serious AE View details

Phase 3 N=506 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Advanced Urothelial Carcinoma · Metastatic Bladder Urothelial Carcinoma · Metastatic Prostate Carcinoma

Primary: Overall Survival (OS) — 14.5; 14.3 months — p=0.1707

National Cancer Institute (NCI) Results Feb 2020 38.8% serious AE View details

Phase 3 N=93 Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Moderate to Severe Convexity of Submental Fat · Safety · Efficacy

Primary: Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating…

Kythera Biopharmaceuticals Results Feb 2020 2.2% serious AE View details

Phase 3 N=324 Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in HbA1c — -1.1; -0.2; -1.2; -0.1 Percentage of HbA1c — p=<0.0001

Novo Nordisk A/S Results Feb 2020 10.5% serious AE View details